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Background: How best to conceptualize problematic pornography use (PPU) and intervene most effectively remain
debated, with obsessive–compulsive disorder (OCD) and addiction frameworks. We investigated the efﬁcacy of the
serotonin-reuptake inhibitor paroxetine in combination with cognitive-behavioral therapy in the treatment of
problematic pornography use (PPU). Case presentation: Three heterosexual males with PPU were treated with
cognitive-behavioral therapy and paroxetine. Frequency of pornography use, other sexual behaviors, and anxiety
were assessed during treatment. Discussion: Paroxetine treatment, although seemingly initially effective in reducing
pornography use and anxiety, appeared related to new compulsive sexual behaviors after 3 months. Conclusions:
Paroxetine may hold promise for short-term reduction of PPU and related anxiety, but new potentially distressing
sexual behaviors may emerge. The cases suggest that PPU may arise from multiple domains. We propose an
explanation of the effects based on recent neuroscientiﬁc research on sexual behaviors and alcohol use.
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INTRODUCTION
About 70% of males aged 18–30 years use pornography
weekly (Hald, 2006). While most view pornography without
problems, some view compulsively and seek treatment
(Gola, Lewczuk, & Skorko, 2016; Gola, Skorko, et al.,
2016). How best to conceptualize problematic pornography
use (PPU) and intervene most effectively remain debated,
with obsessive–compulsive disorder (OCD) and addiction
frameworks (Gola, 2016; Kor, Fogel, Reid, & Potenza,
2013; Kraus, Voon, & Potenza, 2016; Prause, Steele, Staley,
Sabatinelli, & Hajcak, 2016). Paroxetine, due to its efﬁcacy
in OCD and anxiety disorders (Stein, Andersen, Tonnoir, &
Fineberg, 2007) and negative impact on libido (Abler et al.,
2011), has been used in PPU treatment. Here, we report
three cases where paroxetine treatment, although seemingly
initially effective, after 3 months appeared related to new
compulsive sexual behaviors. We place these ﬁndings with-
in the context of neuroscientiﬁc research on compulsive
sexual behaviors and alcohol use.
CASE REPORTS
Patients were Caucasian, heterosexual males [measured
with the Polish adaptation of Kinsey’s Sexual Orientation
Scale (Wierzba et al., 2015)] seeking treatment for PPU
accompanied by compulsive masturbation (characteristics in
Table 1). None took medication, had signiﬁcant medical
problems or histories of risky sexual behaviors, use of paid
sexual services or affairs. All reported some risky alcohol
drinking. Two had episodes of depressive disorder at ages
18 (Mr. A) and 24 (Mr. C) years, respectively. All reported
preoccupations/urges, numerous failed quit attempts, and
signiﬁcant distress related to PPU and masturbation.
Patients attended cognitive-behavioral therapy delivered
by doctoral-level clinical psychologists and completed self-
monitoring reports of pornography consumption (daily) and
anxiety (weekly; Figure 1).
All patients were asked about sexual dysfunction related
to the medication and reported decreased libido and delayed
ejaculation during the initial 2–4 weeks of paroxetine intake
(20 mg/day). Within 10 weeks from the onset of paroxetine
treatment, reported libido was close to the normal and
patients A and B did not experience any difﬁculties in
erection or ejaculation during sexual activity with their
partners or during solitary sexual activity (patient C had
only solitary sexual activity and also did not report
experiencing any troubles). Within the 10 weeks of paroxe-
tine intake, all patients also experienced signiﬁcant
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decreases in self-reported anxiety [A: 45%; B: 50%;
C: 49%; Mbefore = 7.03; SD= .38; Mafter= 3.66; SD= .4;
t(2)= 90.7; and p< .001]. Similarly, frequency of pornog-
raphy consumption decreased, albeit not to a statistically
signiﬁcant level [A: 80%; B: 69%; C: 52%; Mbefore = 7.57;
SD= 2.46; Mafter = 2.25; SD= .28; t(2)= 3.78; and
p= .078]. Interestingly, within 12–14 weeks, new sexual
behaviors appeared. Patients A and C started engaging in
paid sexual relations (up to three times a week), and patient
B initiated an extra-marital affair (with his children’s care
provider). After 13 weeks of treatment, patient C went on
vacation during which he engaged in an almost 2-week-
long paid sexual relationship and quit medication. Due to
those new behaviors, all patients were evaluated for mania/
hypomania according to the criteria presented by Basco
and Rush (2005). Patients A and B were assessed for
symptoms of mania for three consecutive weeks and
patient C for two consecutive weeks. None of the patients
met criteria for mania or hypomania. Interestingly, all of
the new sexual behaviors had a dyadic characteristic and
were not accompanied with rebound of pornography use
and masturbation.
The appearance of new sexual behaviors was discussed
with patients during the meetings. Patient C reported the use
of paid sexual services as having ego-syntonic elements. In
his words, a vacation with paid “girlfriend-like-experiences”
was one of the best times of his life. Patient C declared that
he always preferred dyadic sexual activity over solitary
activity, but due to high anxiety level and difﬁculties in
creating intimate relationships with women, he was more
prone to use pornography and masturbate. Patients A and B
had very strong religious-based beliefs that extra-marital
sexual relationships are morally reprehensible. In the case of
patient A, his ﬁrst use of paid sexual services was described
as having a mixture of pride and guilt. Patient A described
that he always wanted to have sexual experience with
prostitute but was afraid to try. He also wanted to see what
it was like to have sex with another person other than his
girlfriend (who was his ﬁrst sexual partner). His guilt was
related to feeling that he was cheating on his girlfriend in a
manner not consonant with his religious beliefs. A mixture
of pride regarding sexual initiation and engagement and
guilt related to a mismatch of this behavior with his religious
beliefs was present during his sexual encounters. Patient B
also described his extra-marital affair as being characterized
by feelings of both pride and guilt. As in the case of
patient A, his wife had been his ﬁrst and only sexual partner
(with the sexual initiation age of 20 years), and the drive for
the affair involved fascination and a desire “to try something
new.” As patients A and B perceived the new behaviors as
being contrary to their beliefs, yet nonetheless reported
strong motivations to continue the behaviors, paroxetine
treatment was stopped. In the following weeks, Mr. B
reported ending his extra-marital relations, while Mr. A
andMr. C continued engaging in paid sexual services (about
once a week). None of the patients were interested to
increase the amounts of pornography use and frequency of
masturbation (instead of the use of paid sexual services), as
they were describing the pornography use as isolating, time
Table 1. Characteristics of patients
Patient A B C
Age 24 32 35
Relationship
status
In relationship
for 3 years
Married
for 6 years
Single
Occupation Student Manager Software
developer
Onset of porno-
graphy use (age
in years)
11 14 13
Pornography use/
week
12 hr 8 hr 6.5 hr
Frequency of
masturbation/
week
18 8 13
Figure 1. Top: weekly amount of pornography consumption with marked onset and end of paroxetine intake for each subject and onset of
new sexual behaviors appearance. Bottom: weekly rating of anxiety level
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consuming and humiliating. Diminished pornography con-
sumption was sustained through the 3-month follow up for
Mr. A and Mr. B (Mr. C did not follow up). Subsequently,
Mr. A has reported ending his 3-year relationship with his
girlfriend as he had learned that she had been cheating on
him with her ex-partner.
DISCUSSION AND CONCLUSIONS
These cases highlight several important points. In the 1990s,
Dr. Coleman proposed that compulsive sexual behaviors
may be driven by anxiety-reduction mechanisms (Coleman,
1991). Our results are in line with Dr. Coleman’s observa-
tion that PPU may be related to anxiety as both pornography
use and anxiety decreased with paroxetine treatment. Sec-
ond, while paroxetine may hold promise for reducing PPU
and related anxiety, new potentially distressing sexual beha-
viors may emerge. There are several possible explanations
for these observations: (a) new sexual behaviors may be one
symptom of subthreshold hypomania (Fiedorowicz et al.,
2011); (b) paroxetine treatment or refraining from PPU may
have compelled patients to pursue higher risk sexual beha-
viors; (c) patients may have experienced sexual dysfunction
and may have sought more risky or arousing experiences; or,
and (d) in line with recent neuroscientiﬁc ﬁndings (Gola,
Miyakoshi, & Sescousse, 2015; Gola, Wordecha, et al.,
2016; Victor, Sansosti, Bowman, & Hariri, 2015) and older
clinical observations (Coleman, 1991, 2015), PPU may arise
from multiple domains (e.g., with anxious and reward-
related/impulsive components), and paroxetine treatment
may target only anxiety-related aspects.
Our data do not provide convincing support for the ﬁrst
three possibilities. Frequently endorsed symptoms of hypo-
mania, such as unusually high energy, decreased need for
sleep, increased goal-directed activity, grandiosity, or ex-
pansive mood were not observed (Fiedorowicz et al., 2011).
The new sexual behaviors had a dyadic characteristic and
were not accompanied by rebound of PPU and solitary
sexual activity, thus not providing strong support for the
second possibility, although it cannot be completely exclud-
ed. If patients were pursuing more risky or arousing sexual
behavior to overcome sexual dysfunction, we might antici-
pate increases in time spent viewing pornography and
masturbating and new content of pornography being viewed
within the ﬁrst weeks of paroxetine treatment. We did not
observe these patterns. Furthermore, prior to the emergence
of new problematic sexual behaviors, patients were report-
ing the return of normal sexual functioning, suggesting that
the new behaviors were not compensatory to sexual dys-
function. A possibility that ﬁts with the data and warrants
additional study relates to a theory described elsewhere
(Gola et al., 2015) in response to a recent research by
Nikolova et al. on risky alcohol drinking (Nikolova, Knodt,
Radtke, & Hariri, 2015) and Victor et al. on risky sexual
behaviors (Victor et al., 2015). Both theories propose that
imbalances in ventral-striatum-related reward reactivity and
amygdala-related threat reactivity may promote problematic-
alcohol drinking (Nikolova et al., 2015) or sexual risk
taking (Gola et al., 2015; Victor et al., 2015). Problematic
behaviors may result from increased impulsivity (related to
ventral-striatum-related reward reactivity) or increased anxi-
ety (related to amygdala-related threat reactivity). Previous
studies show that anxiety may be diminished with paroxe-
tine, which has been linked to reductions in amygdala’s
volume (Szeszko et al., 2004), while other medications such
as naltrexone may reduce reward responsivity (e.g., craving)
and impulsivity (Bostwick & Bucci, 2008; Raymond,
Grant, & Coleman, 2010; Kraus, Meshberg-Cohen, Martino,
Quinones, & Potenza, 2015). Therefore, we hypothesize that
in PPU, both of the above-mentioned mechanisms may
operate, and this possibility warrants additional investiga-
tion. Although currently speculative, we may explain the
observations in this case series as follows. All three patients
had an initially high level of anxiety (as presented in
Figure 1) and PPU may have helped them regulate their
anxiety. Paroxetine may have helped to decrease amygdala-
related reactivity, resulting in decreased anxiety and subse-
quently decreased PPU. However, at some point, without
targeting craving or reward-related processes, new compul-
sive sexual behaviors may have emerged in the setting of
diminished anxiety. While such mechanisms appear to have
support from experimental studies on sexual behaviors and
problematic alcohol use (Gola et al., 2015; Nikolova et al.,
2015; Victor et al., 2015), they deserve further investigation
in PPU. We are aware that there exists a big leap from three
cases to neuronal mechanisms; however, at the level of
symptoms, the accounts of these three individuals suggest
that anxiety, and reward-related processes may both warrant
strong consideration in the treatment of PPU and perhaps
other compulsive sexual behaviors. Therefore, future clinical
trials should consider combinations of paroxetine and nal-
trexone with careful assessment of sexual behaviors and
individual-difference measures (e.g., impulsivity and anxi-
ety) that may relate to treatment outcome.
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